Xiaofang Zuo

List of Publications by Year
in descending order

189 papers	6,378 citations	70961 41 h-index	102304 66 g-index
193 all docs	193 docs citations	193 times ranked	6059 citing authors

#	Article	IF	Citations
1	Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. Journal of Medicinal Chemistry, 2016, 59, 2849-2878.	2.9	260
2	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. Signal Transduction and Targeted Therapy, 2020, 5, 299.	7.1	232
3	Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. Journal of Medicinal Chemistry, 2020, 63, 12256-12274.	2.9	183
4	8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential. MedChemComm, 2015, 6, 61-74.	3.5	169
5	HIVâ€1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design. Medicinal Research Reviews, 2013, 33, E1-72.	5.0	161
6	Fsp3: A new parameter for drug-likeness. Drug Discovery Today, 2020, 25, 1839-1845.	3.2	156
7	Recent applications of click chemistry in drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 779-789.	2.5	151
8	Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries. Drug Discovery Today, 2016, 21, 118-132.	3.2	138
9	The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic. Journal of Medicinal Chemistry, 2019, 62, 4851-4883.	2.9	124
10	Overview of Recent Strategic Advances in Medicinal Chemistry. Journal of Medicinal Chemistry, 2019, 62, 9375-9414.	2.9	108
11	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. Journal of Medicinal Chemistry, 2016, 59, 7991-8007.	2.9	107
12	Design Strategies of Novel NNRTIs to Overcome Drug Resistance. Current Medicinal Chemistry, 2009, 16, 3903-3917.	1.2	92
13	New techniques and strategies in drug discovery. Chinese Chemical Letters, 2020, 31, 1695-1708.	4.8	82
14	Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: Synthesis and preliminary SAR studies. Bioorganic and Medicinal Chemistry, 2009, 17, 5920-5927.	1.4	81
15	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants. Journal of Medicinal Chemistry, 2017, 60, 4424-4443.	2.9	79
16	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: Optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. European Journal of Medicinal Chemistry, 2015, 92, 754-765.	2.6	76
17	Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: Design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. Bioorganic and Medicinal Chemistry, 2014, 22, 2052-2059.	1.4	71
18	Identification of Dihydrofuro[3,4-d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties. Journal of Medicinal Chemistry, 2019, 62, 1484-1501.	2.9	70

#	Article	IF	Citations
19	Recent developments in the medicinal chemistry of single boron atom-containing compounds. Acta Pharmaceutica Sinica B, 2021, 11, 3035-3059.	5.7	70
20	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. European Journal of Medicinal Chemistry, 2018, 151, 339-350.	2.6	68
21	Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles. Journal of Medicinal Chemistry, 2019, 62, 2083-2098.	2.9	66
22	1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5368-5371.	1.0	65
23	Designed Multiple Ligands: An Emerging Anti-HIV Drug Discovery Paradigm. Current Pharmaceutical Design, 2009, 15, 1893-1917.	0.9	65
24	Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities. European Journal of Medicinal Chemistry, 2020, 190, 112085.	2.6	65
25	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 5775-5781.	1.4	64
26	SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules. Signal Transduction and Targeted Therapy, 2022, 7, 22.	7.1	64
27	Inhibitors of Influenza Virus Polymerase Acidic (PA) Endonuclease: Contemporary Developments and Perspectives. Journal of Medicinal Chemistry, 2017, 60, 3533-3551.	2.9	60
28	1,2,3-Selenadiazole thioacetanilides: Synthesis and anti-HIV activity evaluation. Bioorganic and Medicinal Chemistry, 2009, 17, 6374-6379.	1.4	58
29	Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives. European Journal of Medicinal Chemistry, 2018, 147, 150-162.	2.6	57
30	Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d]pyrimidine non-nucleoside inhibitors. ELife, 2018, 7, .	2.8	57
31	Design, synthesis and biological evaluation of tacrine-1,2,3-triazole derivatives as potent cholinesterase inhibitors. MedChemComm, 2018, 9, 149-159.	3.5	55
32	Sulfanyltriazole/tetrazoles: A Promising Class of HIV-1 NNRTIs. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1014-1023.	1.1	52
33	Recent Advances in the Discovery and Development of Novel HIV-1 NNRTI Platforms: 2006-2008 Update. Current Medicinal Chemistry, 2009, 16, 2876-2889.	1.2	51
34	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: Discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach. European Journal of Medicinal Chemistry, 2014, 85, 293-303.	2.6	51
35	Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library. European Journal of Medicinal Chemistry, 2018, 158, 478-492.	2.6	51
36	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7155-7162.	1.0	50

#	Article	IF	Citations
37	Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2020, 63, 4837-4848.	2.9	50
38	Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators. Journal of Medicinal Chemistry, 2015, 58, 7611-7633.	2.9	49
39	Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 â€“ 2010). Expert Opinion on Therapeutic Patents, 2011, 21, 717-796.	2.4	46
40	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant. Journal of Medicinal Chemistry, 2018, 61, 6379-6397.	2.9	46
41	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 4648-4653.	2.6	45
42	Medicinal chemistry insights in the discovery of novel LSD1 inhibitors. Epigenomics, 2015, 7, 1379-1396.	1.0	42
43	Influenza A virus polymerase: an attractive target for next-generation anti-influenza therapeutics. Drug Discovery Today, 2018, 23, 503-518.	3.2	42
44	Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors. RSC Advances, 2019, 9, 28961-28986.	1.7	42
45	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. European Journal of Medicinal Chemistry, 2015, 93, 330-337.	2.6	41
46	Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities. Journal of Medicinal Chemistry, 2020, 63, 4790-4810.	2.9	41
47	Update on Recent Developments in Small Molecular HIV-1 RNase H Inhibitors (2013-2016): Opportunities and Challenges. Current Medicinal Chemistry, 2018, 25, 1682-1702.	1.2	41
48	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays. Bioorganic and Medicinal Chemistry, 2014, 22, 1863-1872.	1.4	40
49	Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach. Expert Opinion on Drug Discovery, 2016, 11, 857-871.	2.5	39
50	Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016â€“2019). Expert Opinion on Therapeutic Patents, 2019, 29, 871-879.	2.4	39
51	Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs. Acta Pharmaceutica Sinica B, 2020, 10, 878-894.	5.7	39
52	Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel. Journal of Medicinal Chemistry, 2020, 63, 1298-1312.	2.9	37
53	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. European Journal of Medicinal Chemistry, 2014, 87, 52-62.	2.6	36
54	Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014â€“2017). Expert Opinion on Therapeutic Patents, 2018, 28, 299-316.	2.4	36

#	Article	IF	Citations
55	Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza Viral Neuraminidase Inhibitors. Frontiers in Microbiology, 2020, 11, 182.	1.5	36
56	Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate. European Journal of Medicinal Chemistry, 2014, 82, 293-307.	2.6	35
57	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant. Journal of Medicinal Chemistry, 2018, 61, 9976-9999.	2.9	35
58	Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors. Drug Discovery Today, 2019, 24, 629-635.	3.2	35
59	First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via â€˜privileged scaffoldâ€™ refining approach. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5182-5186.	1.0	33
60	Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. European Journal of Medicinal Chemistry, 2017, 136, 144-153.	2.6	33
61	2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies. Journal of Medicinal Chemistry, 2021, 64, 4239-4256.	2.9	33
62	Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors. Acta Pharmaceutica Sinica B, 2022, 12, 581-599.	5.7	33
63	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 3729-3757.	2.9	33
64	Recent Advances in Antiviral Activity of Benzo/Heterothiadiazine Dioxide Derivatives. Current Medicinal Chemistry, 2008, 15, 1529-1540.	1.2	32
65	Arylazolylthioacetanilide. Part 8â˜†: Design, synthesis and biological evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides As Potent HIV-1 inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 5039-5045.	2.6	32
66	Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors. European Journal of Medicinal Chemistry, 2016, 123, 202-210.	2.6	32
67	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the â€œNNRTI Adjacentâ€• Binding Site. ACS Medicinal Chemistry Letters, 2018, 9, 334-338.	1.3	32
68	5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase. European Journal of Medicinal Chemistry, 2018, 155, 714-724.	2.6	31
69	Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities. European Journal of Medicinal Chemistry, 2016, 114, 65-78.	2.6	30
70	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization. European Journal of Medicinal Chemistry, 2017, 130, 209-222.	2.6	30
71	Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP. ACS Medicinal Chemistry Letters, 2017, 8, 1188-1193.	1.3	30
72	Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability. Journal of Medicinal Chemistry, 2020, 63, 10829-10854.	2.9	30

#	Article	IF	Citations
73	Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. European Journal of Medicinal Chemistry, 2014, 80, 112-121.	2.6	29
74	Functional Roles of Azoles Motif in Anti-HIV Agents. Current Medicinal Chemistry, 2011, 18, 29-46.	1.2	28
75	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 109, 294-304.	2.6	28
76	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery. ACS Medicinal Chemistry Letters, 2018, 9, 370-375.	1.3	28
77	Molecular design opportunities presented by solventâ€exposed regions of target proteins. Medicinal Research Reviews, 2019, 39, 2194-2238.	5.0	28
78	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 121, 352-363.	2.6	27
79	Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif. European Journal of Medicinal Chemistry, 2015, 102, 167-179.	2.6	26
80	Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors. European Journal of Medicinal Chemistry, 2018, 146, 220-231.	2.6	26
81	Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries. European Journal of Medicinal Chemistry, 2019, 183, 111696.	2.6	26
82	Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies. European Journal of Medicinal Chemistry, 2020, 206, 112714.	2.6	26
83	Discovery of small molecular inhibitors targeting HIV-1 gp120â€“CD4 interaction drived from BMS-378806. European Journal of Medicinal Chemistry, 2014, 86, 481-490.	2.6	25
84	Discovery of HCV NS5B thumb site I inhibitors: Core-refining from benzimidazole to indole scaffold. European Journal of Medicinal Chemistry, 2015, 94, 218-228.	2.6	24
85	Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. Communications Chemistry, 2019, 2, .	2.0	24
86	Design, synthesis and biological evaluation of â€œMulti-Siteâ€•binding influenza virus neuraminidase inhibitors. European Journal of Medicinal Chemistry, 2019, 178, 64-80.	2.6	24
87	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2019, 27, 447-456.	1.4	24
88	Synthesis and anti-HIV activity evaluation of novel Nâ€²-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides. Medicinal Chemistry Research, 2010, 19, 652-663.	1.1	23
89	1,2,3â€Thiadiazole Thioacetanilides. Part 2. Chemistry and Biodiversity, 2010, 7, 1717-1727.	1.0	23
90	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. Bioorganic and Medicinal Chemistry, 2017, 25, 4397-4406.	1.4	23

#	Article	IF	Citations
91	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP. European Journal of Medicinal Chemistry, 2020, 193, 112237.	2.6	23
92	Punicalagin is a neuraminidase inhibitor of influenza viruses. Journal of Medical Virology, 2021, 93, 3465-3472.	2.5	23
93	An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors. European Journal of Medicinal Chemistry, 2021, 217, 113380.	2.6	23
94	Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1. Expert Opinion on Therapeutic Patents, 2017, 27, 383-391.	2.4	22
95	Efficient drug discovery by rational lead hybridization based on crystallographic overlay. Drug Discovery Today, 2019, 24, 805-813.	3.2	22
96	Multivalent Agents: A Novel Concept and Preliminary Practice in Anti-HIV Drug Discovery. Current Medicinal Chemistry, 2013, 20, 815-832.	1.2	21
97	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2014, 22, 633-642.	1.4	21
98	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 115, 53-62.	2.6	21
99	Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. Expert Opinion on Therapeutic Patents, 2016, 26, 281-289.	2.4	21
100	Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity. European Journal of Medicinal Chemistry, 2020, 187, 111940.	2.6	21
101	Naturally Occurring and Synthetic Bioactive Molecules as Novel Non-Nucleoside HBV Inhibitors. Mini-Reviews in Medicinal Chemistry, 2010, 10, 162-171.	1.1	20
102	Recent advances in the structure-based rational design of TNKSIs. Molecular BioSystems, 2014, 10, 2783-2799.	2.9	20
103	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach. European Journal of Medicinal Chemistry, 2014, 76, 531-538.	2.6	19
104	Design, Synthesis, and Antiâ€<scp>HIV</scp> Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the <scp>NNRTI</scp> Binding Pocket. Chemical Biology and Drug Design, 2015, 86, 122-128.	1.5	18
105	Synthesis and Biological Evaluation of a Series of 2â€((1â€substitutedâ€1Hâ€1,2,3â€triazolâ€4â€yl)methylthio)â€6â€(naphthalenâ€1â€ylmethyl)pyrimidinâ€4(3H)â€one Potential <scp>HIV</scp>â€1 Inhibitors. Chemical Biology and Drug Design, 2015, 86, 614-618.	1.5	17
106	Synthesis and Preliminary Antiviral Activities of Piperidineâ€substituted Purines against <scp>HIV</scp> and Influenza A/H1N1 Infections. Chemical Biology and Drug Design, 2015, 86, 568-577.	1.5	17
107	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. European Journal of Medicinal Chemistry, 2017, 126, 190-201.	2.6	17
108	Targeting the entry step of SARS-CoV-2: a promising therapeutic approach. Signal Transduction and Targeted Therapy, 2020, 5, 98.	7.1	17

#	Article	IF	Citations
109	Multivalent agents: a novel concept and preliminary practice in Anti-HIV drug discovery. Current Medicinal Chemistry, 2013, 20, 815-32.	1.2	17
110	1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries. Bioorganic and Medicinal Chemistry, 2017, 25, 5779-5789.	1.4	16
111	Design, synthesis, and antiviral evaluation of novel hydrazone-substituted thiophene[3,2-d]pyrimidine derivatives as potent human immunodeficiency virus-1 inhibitors. Chemical Biology and Drug Design, 2018, 92, 2009-2021.	1.5	16
112	Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing. European Journal of Medicinal Chemistry, 2019, 182, 111619.	2.6	16
113	Medicinal chemistry insights into novel CDC25 inhibitors. European Journal of Medicinal Chemistry, 2020, 201, 112374.	2.6	16
114	Design, synthesis, and biological evaluation of piperidinylâ€substituted [1,2,4]triazolo[1,5â€a]pyrimidine derivatives as potential antiâ€HIVâ€1 agents with reduced cytotoxicity. Chemical Biology and Drug Design, 2021, 97, 67-76.	1.5	16
115	Boronic acid-containing diarylpyrimidine derivatives as novel HIV-1 NNRTIs: Design, synthesis and biological evaluation. Chinese Chemical Letters, 2021, 32, 4053-4057.	4.8	16
116	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach. Bioorganic and Medicinal Chemistry, 2012, 20, 6795-6802.	1.4	15
117	Design, synthesis, and evaluation of â€œdual-siteâ€•binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase. European Journal of Medicinal Chemistry, 2021, 211, 113063.	2.6	15
118	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties. European Journal of Medicinal Chemistry, 2021, 213, 113051.	2.6	15
119	Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors. European Journal of Medicinal Chemistry, 2021, 226, 113848.	2.6	15
120	Newly Emerging Strategies in Antiviral Drug Discovery: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Anniversary. Molecules, 2022, 27, 850.	1.7	15
121	Blocking Nuclear Import of Pre-Integration Complex: An Emerging Anti-HIV-1 Drug Discovery Paradigm. Current Medicinal Chemistry, 2010, 17, 495-503.	1.2	14
122	Design, synthesis, and biologic evaluation of novel galloyl derivatives as <scp>HIV</scp>â€<scp>RN</scp>ase H inhibitors. Chemical Biology and Drug Design, 2019, 93, 582-589.	1.5	14
123	Medicinal chemistry strategies of targeting HIV-1 capsid protein for antiviral treatment. Future Medicinal Chemistry, 2020, 12, 1281-1284.	1.1	14
124	Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. European Journal of Medicinal Chemistry, 2020, 202, 112495.	2.6	14
125	Discovery of Novel Dihydrothiopyrano[4,3-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles. Journal of Medicinal Chemistry, 2021, 64, 13658-13675.	2.9	14
126	Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents. Archives of Pharmacal Research, 2012, 35, 975-986.	2.7	13

#	Article	IF	Citations
127	Non-nucleoside anti-HBV agents: advances in structural optimization and mechanism of action investigations. MedChemComm, 2015, 6, 521-535.	3.5	13
128	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1348-1351.	1.0	13
129	Discovery of potent <scp>HIV</scp>â€1 nonâ€nucleoside reverse transcriptase inhibitors by exploring the structureâ€“activity relationship of solventâ€exposed regions I. Chemical Biology and Drug Design, 2019, 93, 430-437.	1.5	13
130	Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity. European Journal of Medicinal Chemistry, 2021, 212, 113097.	2.6	13
131	Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors. European Journal of Medicinal Chemistry, 2021, 225, 113780.	2.6	13
132	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. Bioorganic and Medicinal Chemistry, 2016, 24, 4424-4433.	1.4	12
133	Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5â€b]pyridinâ€2â€ylthioacetanilides as Potent HIV NNRTIs Via a Structureâ€based Bioisosterism Approach. Chemical Biology and Drug Design, 2016, 88, 241-253.	1.5	12
134	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs. European Journal of Medicinal Chemistry, 2017, 140, 383-391.	2.6	12
135	Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase. Bioorganic and Medicinal Chemistry, 2019, 27, 3836-3845.	1.4	12
136	Discovery of novel anti-influenza agents via contemporary medicinal chemistry strategies (2014â€“2018) Tj ETQq0 0 0 rgBT /Overlock 1	1.1	12
137	Structureâ€“Activity Relationship Exploration of NNIBP Tolerant Region I Leads to Potent HIV-1 NNRTIs. ACS Infectious Diseases, 2020, 6, 2225-2234.	1.8	12
138	Discovery of potent and selective Cdc25 phosphatase inhibitors via rapid assembly and in situ screening of Quinonoid-focused libraries. Bioorganic Chemistry, 2021, 115, 105254.	2.0	12
139	Identification of C5-NH₂ Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability. Journal of Medicinal Chemistry, 2021, 64, 17992-18009.	2.9	12
140	Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability. Journal of Medicinal Chemistry, 2022, 65, 4218-4237.	2.9	12
141	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 5290-5297.	1.4	11
142	3D-QSAR and docking studies on piperidine-substituted diarylpyrimidine analogues as HIV-1 reverse transcriptase inhibitors. Medicinal Chemistry Research, 2015, 24, 3314-3326.	1.1	11
143	One-minute self-assembly of millimetre-long DAST crystalline microbelts via substrate-supported rapid evaporation crystallization. RSC Advances, 2017, 7, 31691-31695.	1.7	11
144	The development of an effective synthetic route of lesinurad (RDEA594). Chemistry Central Journal, 2017, 11, 86.	2.6	11

#	Article	IF	Citations
145	Resurrecting the Condemned: Identification of N-Benzoxaborole Benzofuran GSK8175 as a Clinical Candidate with Reduced Metabolic Liability. Journal of Medicinal Chemistry, 2019, 62, 3251-3253.	2.9	11
146	Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer. Frontiers in Oncology, 2019, 9, 236.	1.3	11
147	Design, synthesis, and evaluation of novel heteroaryldihydropyrimidine derivatives as nonâ€nucleoside hepatitis B virus inhibitors by exploring the solventâ€exposed region. Chemical Biology and Drug Design, 2020, 95, 567-583.	1.5	11
148	Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C. Bioorganic and Medicinal Chemistry, 2021, 30, 115927.	1.4	11
149	Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stability. European Journal of Medicinal Chemistry, 2022, 227, 113903.	2.6	11
150	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2. Bioorganic and Medicinal Chemistry, 2018, 26, 2051-2060.	1.4	10
151	Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors. Expert Opinion on Drug Discovery, 2019, 14, 915-931.	2.5	10
152	Designing influenza polymerase acidic endonuclease inhibitors via â€˜privileged scaffoldâ€™ re-evolution/refining strategy. Future Medicinal Chemistry, 2019, 11, 265-268.	1.1	10
153	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. European Journal of Medicinal Chemistry, 2020, 206, 112811.	2.6	10
154	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2021, 64, 13604-13621.	2.9	10
155	Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C. Journal of Medicinal Chemistry, 2022, 65, 2458-2470.	2.9	10
156	Cosalane and its Analogues: A Unique Class of Anti-HIV Agents. Mini-Reviews in Medicinal Chemistry, 2010, 10, 966-976.	1.1	9
157	Design, synthesis and biological evaluation of novel trimethylpyrazine-2-carbonyloxy-cinnamic acids as potent cardiovascular agents. MedChemComm, 2014, 5, 711.	3.5	9
158	Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities. Expert Opinion on Drug Discovery, 2015, 10, 1271-1281.	2.5	9
159	Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2). Expert Opinion on Therapeutic Patents, 2017, 27, 9-15.	2.4	9
160	Discovery and optimizing polycyclic pyridone compounds as anti-HBV agents. Expert Opinion on Therapeutic Patents, 2020, 30, 715-721.	2.4	9
161	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors. European Journal of Medicinal Chemistry, 2021, 225, 113769.	2.6	9
162	Novel RNase H Inhibitors Blocking RNA-directed Strand Displacement DNA Synthesis by HIV-1 Reverse Transcriptase. Journal of Molecular Biology, 2022, 434, 167507.	2.0	9

#	Article	IF	Citations
163	Discovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach. MedChemComm, 2013, 4, 810.	3.5	8
164	Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. MedChemComm, 2013, 4, 827-832.	3.5	8
165	Repurposing of HDAC inhibitors toward anti-hepatitis C virus drug discovery: teaching an old dog new tricks. Future Medicinal Chemistry, 2015, 7, 1367-1371.	1.1	8
166	Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-yloxy)acetamide Derivatives as Potential Anti-HIV-1 Agents. Chemical Biology and Drug Design, 2016, 87, 283-289.	1.5	8
167	Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182. Expert Opinion on Therapeutic Patents, 2016, 26, 979-986.	2.4	8
168	Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIVâ€‘1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2022, 53, 116531.	1.4	8
169	HIV-1 capsid inhibitors: a sword to destroy the virus. Future Medicinal Chemistry, 2022, 14, 605-607.	1.1	8
170	Identification of spirocyclic or phosphate substituted quinolizine derivatives as novel HIV-1 integrase inhibitors: a patent evaluation of WO2016094197A1, WO2016094198A1 and WO2016154527A1. Expert Opinion on Therapeutic Patents, 2017, 27, 1277-1286.	2.4	7
171	Discovery of novel â€œDual-siteâ€•binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors. European Journal of Medicinal Chemistry, 2020, 191, 112147.	2.6	7
172	Design, Synthesis, and Biological Evaluation of Novel 4â€Aminopiperidinylâ€linked 3,5â€Disubstitutedâ€1,2,6â€thiadiazineâ€1,1â€dione Derivatives as <scp>HIV</scp>â€1 <scp>NNRTI</scp>s. Chemical Biology and Drug Design, 2015, 86, 107-113.	1.5	6
173	Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket. European Journal of Medicinal Chemistry, 2021, 214, 113204.	2.6	6
174	From design to biological mechanism evaluation of phenylalanine-bearing HIV-1 capsid inhibitors targeting a vital assembly interface. Chinese Chemical Letters, 2023, 34, 107611.	4.8	6
175	Facile Synthesis of Derivatives of 1,1,3â€Trioxoâ€2H,4Hâ€pyrrolo[1,2â€b][1,2,4,6]thiatriazine: A New Heterocyclic System. Heteroatom Chemistry, 2013, 24, 495-501.	0.4	5
176	Development of a practical synthesis of etravirine via a microwave-promoted amination. Chemistry Central Journal, 2018, 12, 144.	2.6	5
177	Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses. Advances in Experimental Medicine and Biology, 2021, 1322, 219-260.	0.8	5
178	The development of an effective synthetic route of rilpivirine. BMC Chemistry, 2021, 15, 22.	1.6	5
179	SARS-CoV-2 Entry Inhibitors Targeting Virus-ACE2 or Virus-TMPRSS2 Interactions. Current Medicinal Chemistry, 2022, 29, 682-699.	1.2	5
180	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2021, 40, 116195.	1.4	5

#	Article	IF	Citations
181	Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP. Bioorganic Chemistry, 2021, 116, 105353.	2.0	5
182	Substituted indoles as HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent evaluation (WO2015044928). Expert Opinion on Therapeutic Patents, 2016, 26, 629-635.	2.4	4
183	Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors. Bioorganic and Medicinal Chemistry, 2021, 48, 116414.	1.4	4
184	Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127287.	1.0	3
185	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. Bioorganic and Medicinal Chemistry, 2021, 42, 116239.	1.4	3
186	Design, synthesis, and biological evaluation of novel 5â€Alkylâ€6â€Adamantylmethylpyrimidinâ€4(3H)â€ones as <scp>HIV</scp>â€1 nonâ€nucleoside reverseâ€transcriptase inhibitors. Chemical Biology and Drug Design, 2016, 88, 380-385.	1.5	2
187	The increasing impact of Chinese innovative drug research on the global stage with a focus on drug discovery. Expert Opinion on Drug Discovery, 2020, 15, 1115-1120.	2.5	2
188	Discovery of Bioactive Molecules via Miniaturized Parallel Modular Reactions and Rapid Screening (2016-2021 update). Mini-Reviews in Organic Chemistry, 2021, 18, .	0.6	0
189	Application of Multi-component Reactions in Seeking Bioactive Molecules. Mini-Reviews in Organic Chemistry, 2022, 19, .	0.6	0